8-K: 22nd Century Group Secures Shareholder Approval for Key Proposals, Adjourns Vote on Share Increase

22nd Century Group successfully passed several proposals at its special meeting, including a reverse stock split and warrant issuance, but adjourned the vote on increasing authorized shares to February 15th.

Summary

• 22nd Century Group held a special meeting of stockholders on January 24, 2024, where several proposals were voted on.
• The proposal to approve a reverse stock split at a ratio between 1-for-2 and 1-for-16 was approved with 21,678,116 votes for, 7,225,428 against, and 218,772 abstaining.
• A proposal to increase the number of authorized shares from 66,666,667 to 250,000,000 was not fully approved and was adjourned to February 15, 2024, with 20,785,163 votes for, 8,114,389 against, and 222,764 abstaining.
• The issuance of shares upon exercise of warrants was approved with 15,798,872 votes for, 4,135,656 against, 117,841 abstaining, and 9,069,947 broker non-votes.
• A proposal to adjourn the meeting if necessary was approved with 21,718,539 votes for, 7,138,191 against, and 265,586 abstaining.
• The meeting was adjourned solely with respect to the proposal to increase authorized shares to allow more time for shareholders to vote.
• The reconvened meeting will take place on February 15, 2024, at 11:00 a.m. Eastern Time in San Diego, CA.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the approval of key proposals and management's focus on cost reduction and business transformation, but the adjournment of the vote on increasing authorized shares introduces some uncertainty.

Positives

• Shareholders approved the reverse stock split, which is intended to help the company comply with Nasdaq listing rules.
• The approval of the warrant issuance provides the company with potential capital.
• The company is actively working to improve its tobacco business margins and increase returns from those assets.
• Management is focused on transforming the business into a lean operating base and extending the cash runway.

Negatives

• The proposal to increase the number of authorized shares was not fully approved and was adjourned, indicating some shareholder resistance.
• The adjournment of the vote on increasing authorized shares suggests the company may face challenges in securing the necessary capital for strategic needs.

Risks

• The company may not be able to secure enough votes to pass the proposal to increase authorized shares on February 15th.
• Failure to increase authorized shares could limit the company's ability to address strategic needs and achieve self-sustaining operations.
• The company's turnaround efforts are still in progress, and there is no guarantee of success.
• The company's future performance is subject to risks outlined in their annual and quarterly reports.

Future Outlook

The company aims to achieve self-sustaining operations and is working to improve its tobacco business margins. The company is seeking shareholder approval for an increase in authorized shares to address strategic needs.

Management Comments

• We sincerely appreciate the support of our stockholders on these important items as we work to swiftly effect a turnaround of the business, stated Larry Firestone, Chairman and Chief Executive Officer of 22nd Century.
• In the seven weeks since I joined the Company, we have fully focused the business on our tobacco operations, implemented aggressive operating cost reductions and extended our balance sheet runway.
• While I am pleased with the progress on these and other initiatives we have underway, Proposal 2 is still critically important to ensuring that the Company can address any strategic needs as we bridge to self-sustaining operations as quickly as possible.

Industry Context

The company operates in the agricultural biotechnology sector, focusing on tobacco harm reduction and plant science. The company's efforts to obtain FDA approval for its reduced nicotine products and its focus on cost reduction are in line with industry trends towards health and wellness and operational efficiency.

Comparison to Industry Standards

• The company's focus on reduced nicotine tobacco aligns with the broader industry trend towards harm reduction, similar to companies like Philip Morris International which are also investing in reduced risk products.
• The reverse stock split is a common strategy for companies facing delisting from exchanges, similar to actions taken by other small-cap biotech firms.
• The company's efforts to improve margins and reduce costs are consistent with industry-wide pressures to improve profitability, similar to other companies in the consumer goods and biotechnology sectors.

Stakeholder Impact

• Shareholders will be impacted by the reverse stock split and the potential increase in authorized shares.
• Employees may be affected by the company's cost reduction efforts.
• Customers may benefit from the company's focus on improving its tobacco business and increasing VLN sales.

Next Steps

• The company will reconvene the Special Meeting on February 15, 2024, to vote on the proposal to increase the number of authorized shares.
• The company will continue to focus on its tobacco operations, cost reductions, and extending its balance sheet runway.

Key Dates

Keywords

reverse stock split, authorized shares, warrant issuance, shareholder vote, Nasdaq listing rules, tobacco operations, cost reductions, biotechnology, plant science, turnaround